Emergent commences dosing in Phase 2 trial of NuThrax anthrax vaccine

Specialty pharmaceutical company Emergent BioSolutions has dosed the first subject in the Phase 2 trial evaluating anthrax vaccine NuThrax that is adsorbed in combination with CPG 7909 immunostimulatory adjuvant.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news